Nippon Shinyaku, meanwhile, is weighing next steps after its drug Viltepso didn’t outperform a placebo in a Phase 3 study.
OOpsy. Sofdra has no such worries. Best in class.
Certainly unlike me in grade three that's for sure.
Ann: Botanix Commercial Day Webinar Presentation, page-196
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $671.1M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 38.0¢ | 36.5¢ | $827.7K | 2.229M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 99032 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 13677 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |